The last few months have certainly been a very busy period, not only for Immutep but for our whole sector. I would like to take the opportunity in our newsletter to add a bit more colour to the significance of Bristol Myers Squibb’s (BMS) first validation of a LAG-3 product, and to elaborate on our second collaboration with MSD and our partnership with LabCorp to help develop immuno oncology diagnostics.
From an industry perspective, March 2021 delivered the news we had all been anticipating for years: the validation of LAG-3 as the next emerging immunotherapy target.
For more information, download the attached PDF.
Download this document
